Legato Capital Management LLC Purchases Shares of 6,783 Kymera Therapeutics, Inc. $KYMR

Legato Capital Management LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,783 shares of the company’s stock, valued at approximately $384,000.

A number of other hedge funds have also recently made changes to their positions in KYMR. Commodore Capital LP acquired a new stake in shares of Kymera Therapeutics in the 2nd quarter worth about $32,730,000. Federated Hermes Inc. purchased a new stake in shares of Kymera Therapeutics in the third quarter worth approximately $31,622,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after purchasing an additional 491,737 shares in the last quarter. Millennium Management LLC boosted its position in shares of Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after buying an additional 394,562 shares during the last quarter. Finally, Frontier Capital Management Co. LLC grew its holdings in Kymera Therapeutics by 272.7% during the second quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after buying an additional 359,847 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have weighed in on KYMR shares. Royal Bank Of Canada restated an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Mizuho raised their price target on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Stifel Nicolaus set a $114.00 price target on shares of Kymera Therapeutics in a report on Monday, December 8th. HC Wainwright increased their price objective on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Oppenheimer boosted their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $86.11 on Thursday. The firm’s fifty day moving average price is $78.75 and its 200-day moving average price is $66.40. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The stock has a market cap of $7.03 billion, a P/E ratio of -23.40 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business’s revenue was down 60.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.88) EPS. Sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 4,895 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total value of $417,543.50. Following the transaction, the chief financial officer owned 232,588 shares of the company’s stock, valued at $19,839,756.40. This represents a 2.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce Booth sold 81,866 shares of Kymera Therapeutics stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $90.13, for a total transaction of $7,378,582.58. Following the sale, the director directly owned 675,341 shares of the company’s stock, valued at $60,868,484.33. This represents a 10.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 561,698 shares of company stock valued at $50,388,337 over the last quarter. Company insiders own 16.01% of the company’s stock.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: UBS raised its price target to $128 and maintained a Buy rating, implying meaningful upside vs. the current level — this is a material analyst catalyst that can support upside interest. UBS price target raise
• Positive Sentiment: Analyst coverage and commentary highlight Kymera’s strong cash position (~$1.6B) and advancing degraders (KT‑621, KT‑579) into mid‑stage trials — these program milestones (2026–2027 catalysts) underpin medium‑term upside. Seeking Alpha pipeline write-up
• Positive Sentiment: Recent press roundups note broad analyst bullishness on select healthcare names including Kymera, which can help sustain investor interest from institutions and momentum traders. Globe and Mail analyst roundup
• Neutral Sentiment: Fundamentals remain mixed: recent quarterly results included a revenue shortfall and wider losses, which keep near‑term valuation sensitive to execution and clinical readouts. (Context referenced in analyst coverage above.) Seeking Alpha: financial context
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M) — a ~10.8% reduction in his holding — which is a notable insider disposition that may create near‑term selling pressure or prompt investor questions about timing. Bruce Booth Form 4
• Negative Sentiment: Multiple executive sales: CFO Bruce Jacobs, COO Jeremy Chadwick and insider Jared Gollob completed several transactions across March 2–4 totaling tens of thousands of shares at prices in the mid‑$80s to ~$90 — cumulative insider selling raises short‑term supply concerns. Insider filings

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.